Business
Director Dealing
On September 30, 2025, 4basebio PLC announced that CEO Dr. Heikki Lanckriet purchased 2,000 ordinary shares on September 29, 2025. The aggregated purchase price was 749 pence. Following this transaction, Dr. Lanckriet's total shareholding is 1,119,688 shares, representing 7.21% of the company's issued share capital. The 2,000 shares acquired represent approximately 0.01% of the company's issued share capital, which comprises 15,538,518 ordinary shares. The transactions took place on the London Stock Exchange. Disclaimer*
About this update from 4basebio Plc
30 September 2025 4basebio PLC (" 4basebio " or the " Company ") Director Dealing Cambridge, UK, 30 September 2025 – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that it was informed by Dr. Heikki Lanckriet, CEO of the Company, that on 29 September 2025 he made the following purchase in ordinary shares in the capital of the Company through the market. Further details are set out in the Notification of Dealing Form below. Director / PCA Number of Ordinary Shares Acquired Purchase Price (Aggregated) (p) Shareholding Following Acquisition Shareholding Following Acquisition as a Percentage of Issued Share Capital Heikki Lanckriet 2,000 749 1,119,688 7.21% The 2,000 additional shares purchased represent approximately 0.01 per cent. of the Company's issued share capital. The issued share capital of the Company comprises 15,538,518 ordinary shares. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310. For further enquiries, please contact: 4basebio PLC Dr. Heikki Lanckriet, CEO +44 (0) 1223 967 943 Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes +44 (0) 20 7213 0880 Joint Broker RBC Capital Markets Kathryn Deegan / Matthew Coakes +44 (0) 20 7653 4000 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks +44 (0) 20 7220 0500 Notes to Editors About 4basebio 4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients. Forward-looking statements This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different. Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 1 Details of the persons discharging managerial responsibilities / person closely associated a) Name Heikki Lanckriet 2 Reason for the notification a) Position/Status Chief Executive Officer b) Initial notification/ Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name 4basebio plc b) LEI 213800E2DX9EAIUNCB30 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Ordinary Shares ISIN: GB00BMCLYF79 b) Nature of the transaction Acquisition of ordinary shares c) Price(s) and volume(s) Date Price(s) Volume(s) 29/09/2025 750p 1,000 29/09/2025 748p 1,000 d) Aggregated information - Aggregated volume - Aggregated Price 2,000 749p e) Date of transaction 29 September 2025 f) Place of transaction London Stock Exchange